Klaus Pantel, Chairman of the Institute of Tumor Biology at University Medical Center Hamburg-Eppendorf, reviews how liquid biopsy analyses can provide information for the early detection of cancer and identify cancer patients at risk of relapse. The approach may also serve to monitor tumor evolution, therapeutic targets, or mechanisms of resistance on metastatic cells.
Liquid biopsies show particular promise for metastatic cancers. Repeated needle biopsies of metastatic lesions are invasive and some locations are difficult to access. In contrast, monitoring of blood samples is only minimally invasive and can identify tumor evolution and tumor subtype switches, which may then lead to the selection of appropriate therapies based on the molecular composition of recurrent metastases.
Prof. Klaus Pantel also discusses the importance of technical standardization and clinical validation of liquid biopsy assays.
Dr. Alexander Sartori from Agena Bioscience follows up with an overview of Agena’s MassARRAY® System and available variant panels for circulating cell-free DNA in various cancers.
Recorded September 30, 2021